Gufic BioSciences, an Indian pharmaceutical company, released its Q1 financial results. Consolidated revenue increased by 10.3% to ₹223.72 crore, up from ₹202.81 crore in the previous year. However, net profit declined by 37.3% to ₹13.07 crore from ₹20.86 crore. EBITDA decreased by 9.8% to ₹32.30 crore, with the EBITDA margin falling by 339 basis points to 14.25%. The company faced increased material costs, higher employee benefits expenses, and doubled finance costs. Gufic BioSciences continues to operate solely in the pharmaceuticals segment.
30May 25
Gufic Biosciences Reports Mixed Q4 Results: Revenue Up, Profits Down
Gufic Biosciences' Q4 financial results show a 5.13% increase in revenue to ₹2.05 billion, but a significant decline in profitability. EBITDA fell to ₹266.00 million from ₹342.30 million year-over-year, with EBITDA margin dropping to 12.99% from 17.55%. Net profit sharply decreased to ₹80.00 million from ₹200.00 million in the previous year. The company faces challenges in maintaining profit margins despite revenue growth.